Average Weight Loss at 18 Months

Ozempic (semaglutide) is available in 0.5 mg, 1.0 mg, and 2.0 mg doses, originally approved for type 2 diabetes. The SUSTAIN trials ranged from 30 to 104 weeks in duration. At 18 months:

• Ozempic 1.0 mg: Average weight loss of approximately 6% to 9% of body weight. For a 230-pound person, that is roughly 14 to 21 pounds .
• Ozempic 2.0 mg: The higher dose, approved more recently, produces somewhat greater weight loss, estimated at 8% to 12% of body weight based on available data .

Keep in mind that Ozempic's maximum dose is lower than Wegovy's (2.0 mg vs 2.4 mg), which is one reason Ozempic's weight loss numbers are somewhat lower than Wegovy in direct comparisons. However, many patients achieve meaningful, sustained results on Ozempic that significantly improve their metabolic health.

Timeline from Start to 18 Months

• Months 1 to 2 (0.25 mg to 0.5 mg): Titration. Weight loss of 2 to 5 pounds. Appetite adjustment. Common GI side effects (nausea, bloating) are most pronounced.
• Months 3 to 5 (0.5 mg to 1.0 mg): Therapeutic dosing begins. Cumulative loss of 6 to 14 pounds. Many patients notice clearly reduced hunger and smaller meal portions.
• Months 6 to 9 (1.0 mg to 2.0 mg maintenance): Peak loss rate. Cumulative loss of 12 to 20 pounds. Blood sugar improvements are significant for diabetic patients. A1C may drop by 1.0% to 1.8%.
• Months 10 to 13: Loss rate begins to slow. Cumulative loss of 16 to 24 pounds. Body is adapting to lower weight. Side effects have generally stabilized.
• Months 14 to 18: Plateau territory for most patients. Cumulative loss of 14 to 27 pounds. The medication continues to maintain weight loss and blood sugar control.

Ozempic's Strengths at 18 Months

While Ozempic may not produce the same total weight loss as higher-dose options, it offers several advantages for long-term use:

• Proven diabetes management: Ozempic is first and foremost a diabetes medication. A1C reductions of 1.0% to 1.8% are well-documented across the SUSTAIN program, and these improvements are sustained through 18 months .
• Cardiovascular protection: SUSTAIN 6 demonstrated a 26% reduction in major adverse cardiovascular events over 2 years .
• Insurance coverage: Ozempic is more broadly covered by insurance plans than Wegovy or Zepbound, particularly for patients with a diabetes diagnosis.
• Well-established safety profile: Years of post-market surveillance provide confidence in long-term safety.
• Kidney protection: The FLOW trial demonstrated that semaglutide reduced the progression of chronic kidney disease by 24% .

Side Effects at 18 Months

By 18 months, most patients have a stable, comfortable relationship with the medication:

• GI issues: Nausea affects fewer than 5% of patients at this stage. Constipation and diarrhea are the most common lingering complaints, but they are typically mild.
• Injection fatigue: Some patients report psychological fatigue from weekly injections after 18 months. Rotating injection sites and establishing a consistent routine helps.
• Gallbladder events: The risk of gallstones is elevated with any weight loss exceeding 5% of body weight. Report right-sided abdominal pain promptly .
• Nutrient deficiencies: Extended reduced food intake can lead to low levels of B12, iron, or vitamin D. Periodic blood work helps catch and correct deficiencies.

Tips for Long-Term Success on Ozempic

• Focus on metabolic health, not just weight: Track A1C, blood pressure, cholesterol, and liver enzymes alongside the scale.
• Eat nutrient-dense foods: With reduced appetite, every meal matters more. Prioritize lean protein, vegetables, whole grains, and healthy fats.
• Maintain physical activity: Regular exercise supports insulin sensitivity and helps prevent muscle loss. Aim for a mix of cardio and resistance training.
• Stay in regular contact with your provider: Lab work every 3 to 6 months and periodic medication reviews keep your treatment on track.
• Consider dose optimization: If you are on 1.0 mg and want more weight loss, discuss the 2.0 mg dose with your doctor.
• Plan for the long term: Ozempic works best as an ongoing treatment. Discuss your multi-year plan with your provider.

Frequently Asked Questions

Should I switch from Ozempic to Wegovy for more weight loss?

If weight loss is your primary goal and you have maximized your Ozempic dose, switching to Wegovy (semaglutide 2.4 mg) may offer additional benefit. The active ingredient is identical, but Wegovy's higher maximum dose often produces more weight loss. Insurance and access considerations may factor into this decision $1,300-$1,400/mo (brand).

Is 18 months of Ozempic safe?

Yes. Ozempic has been studied in trials lasting up to 2 years and has been on the market since 2017. Long-term safety data is extensive and reassuring. Continue regular monitoring with your physician .

Why is my weight loss less than what I read about online?

Online reports often feature dramatic results that may not reflect the average. Ozempic at its approved doses (0.5 to 2.0 mg) produces moderate, steady weight loss rather than the dramatic drops seen with higher-dose semaglutide (Wegovy 2.4 mg) or tirzepatide. Your individual genetics, metabolism, diet, and activity level also play significant roles.

Can I take Ozempic indefinitely?

Ozempic is approved for long-term use in type 2 diabetes, and many patients take it for years. For weight management specifically, ongoing treatment is typically recommended since stopping leads to weight regain in most cases .

What lab work should I get at 18 months?

At minimum: A1C, fasting glucose, complete lipid panel, liver function tests (ALT, AST), kidney function (creatinine, eGFR), thyroid panel, B12, vitamin D, and a complete blood count. Share results with your prescribing provider for interpretation.

Optimize Your Ozempic Treatment

Eighteen months on Ozempic is a strong foundation for ongoing health improvement. Whether you want to fine-tune your current treatment or explore additional options, expert guidance is essential. FormBlends connects patients with licensed providers experienced in long-term GLP-1 management.

Schedule a consultation to review your 18-month results and plan forward.